at Investor's Business Daily (Jan 20, 2015)
The FDA says Johnson & Johnson's (JNJ +0.1%) diabetes drug Invokana was effective at lowering a key measure of blood sugar, but the agency raised concerns about potential stroke and bone-related safety risks. The drug is due to be reviewed on Thursday by the FDA's endocrinologic and metabolic drugs advisory committee, which is made up of non-FDA medical experts. The agency released its review of the product today in preparation for the panel meeting.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Jan 20, 2015)
at CNBC.com (Jan 20, 2015)
Pre-Market Earnings Report for January 20, 2015 : JNJ, MS, DAL, HAL, BHI, MTB, RF, IGTE, ATI, EDU, MTG, SAPat Nasdaq.com (Jan 16, 2015)
at CNBC.com (Jan 16, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs